Mutual of America Capital Management LLC Sells 1,217 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

Mutual of America Capital Management LLC reduced its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 8.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,660 shares of the company’s stock after selling 1,217 shares during the period. Mutual of America Capital Management LLC’s holdings in Myriad Genetics were worth $374,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Myriad Genetics by 0.8% in the first quarter. Vanguard Group Inc. now owns 10,035,708 shares of the company’s stock valued at $213,961,000 after purchasing an additional 81,475 shares during the period. Earnest Partners LLC raised its stake in Myriad Genetics by 3.5% during the 2nd quarter. Earnest Partners LLC now owns 4,072,018 shares of the company’s stock valued at $99,602,000 after purchasing an additional 138,960 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Myriad Genetics by 2.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,776,959 shares of the company’s stock valued at $67,924,000 after purchasing an additional 75,445 shares during the period. Sei Investments Co. increased its stake in Myriad Genetics by 5.4% during the second quarter. Sei Investments Co. now owns 2,417,192 shares of the company’s stock valued at $59,125,000 after acquiring an additional 124,007 shares during the period. Finally, Disciplined Growth Investors Inc. MN raised its stake in shares of Myriad Genetics by 0.5% in the second quarter. Disciplined Growth Investors Inc. MN now owns 2,087,328 shares of the company’s stock valued at $51,056,000 after purchasing an additional 10,035 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Insider Buying and Selling

In related news, CEO Paul J. Diaz sold 15,000 shares of the stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the sale, the chief executive officer now directly owns 962,378 shares in the company, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Colleen F. Reitan sold 46,012 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $27.95, for a total transaction of $1,286,035.40. Following the transaction, the director now owns 42,533 shares of the company’s stock, valued at approximately $1,188,797.35. This represents a 51.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,012 shares of company stock valued at $1,900,485 over the last ninety days. Insiders own 2.10% of the company’s stock.

Myriad Genetics Stock Performance

Shares of NASDAQ:MYGN opened at $16.28 on Thursday. The stock has a market capitalization of $1.48 billion, a P/E ratio of -12.52 and a beta of 1.93. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. Myriad Genetics, Inc. has a 1-year low of $14.72 and a 1-year high of $29.30. The business has a 50-day moving average price of $21.77 and a two-hundred day moving average price of $24.35.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MYGN shares. Morgan Stanley dropped their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating for the company in a report on Monday, November 18th. StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. TD Cowen boosted their target price on Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Scotiabank raised their price target on Myriad Genetics from $29.00 to $34.00 and gave the company a “sector outperform” rating in a report on Tuesday, August 13th. Finally, Wells Fargo & Company initiated coverage on Myriad Genetics in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $35.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $27.36.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.